Clinical tumor size after chemotherapy, median (range), cm |
1.4 (0-15.8) |
1.2 (0-11.0) |
1.2 (0-12.5) |
1.5 (0-15.8) |
0.10 |
Clinical response |
|
|
|
|
0.48 |
Complete response |
166 (27.4) |
36 (24.0) |
58 (33.3) |
72 (25.4) |
|
Partial response |
324 (53.4) |
83 (55.3) |
89 (51.2) |
152 (53.7) |
|
Stable disease |
79 (13.0) |
20 (13.3) |
19 (10.9) |
40 (14.1) |
|
Disease progression |
38 (6.3) |
11 (7.3) |
8 (4.6) |
19 (6.7) |
|
Unknown |
87 |
20 |
33 |
34 |
|
Pathologic response, breast tumor |
|
|
|
|
<0.0001 |
Complete response |
233 (33.8) |
81 (47.9) |
103 (50.2) |
49 (15.5) |
|
Partial response |
318 (46.1) |
60 (35.5) |
80 (39.0) |
178 (56.3) |
|
Stable disease |
96 (13.9) |
22 (13.0) |
15 (7.3) |
59 (18.7) |
|
Disease progression |
43 (6.2) |
6 (3.6) |
7 (3.4) |
30 (9.5) |
|
Unknown |
4 |
1 |
2 |
1 |
|
Pathologic tumor size in cases with residual disease, median (range), cm |
1.8 (0.1-22.5) |
1.8 (0.1-9.0) |
1.7 (0.1-9.0) |
2.0 (0.1-22.5) |
0.026 |
Pathologic N category |
|
|
|
|
<0.0001 |
N0 |
285 (41.1) |
84 (49.4) |
134 (64.7) |
67 (21.1) |
|
N1 |
241 (34.7) |
55 (32.4) |
53 (25.6) |
133 (43.0) |
|
N2 |
129 (18.6) |
26 (15.3) |
16 (7.7) |
87 (27.4) |
|
N3 |
39 (5.6) |
5 (2.9) |
4 (1.9) |
30 (9.5) |
|
Unknown |
0 |
0 |
0 |
0 |
|
Largest lymph node metastasis in cases with residual positive nodes, median (range), cm |
0.9 (0.01-8.0) |
1.0 (0.01-4.5) |
0.7 (0.04-4.0) |
0.9 (0.01-8.0) |
0.056 |
Number of breast operations |
|
|
|
|
0.039 |
1 |
643 (92.7) |
164 (96.5) |
193 (93.2) |
286 (90.2) |
|
2 or more |
51 (7.3) |
6 (3.5) |
14 (6.8) |
31 (9.8) |
|
Final breast surgery |
|
|
|
|
0.019 |
Breast-conserving surgery |
277 (40.0) |
79 (46.8) |
89 (43.0) |
109 (34.5) |
|
Mastectomy |
415 (60.0) |
90 (53.2) |
118 (57.0) |
207 (65.5) |
|
pCR (breast and axilla) |
195 (28.1) |
65 (38.2) |
94 (45.4) |
36 (11.4) |
<0.0001 |
pCR in breast only |
233 (33.6) |
81 (47.6) |
103 (49.8) |
49 (15.5) |
<0.0001 |
pCR in axilla only |
285 (41.1) |
84 (49.4) |
134 (64.7) |
67 (21.1) |
<0.0001 |